A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms BRILLIANCE
- Sponsors Janssen; Janssen Research & Development
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 05 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
- 22 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.